Dexamethasone potentiates chimeric antigen receptor T cell persistence and function by enhancing IL-7Rα expression
Ashlie Munoz, Ryan Urak, Ellie Taus, Hui-Ju Hsieh, Dennis Awuah, Vibhuti Vyas, Laura Lim, Katherine Jin, Shu‐Hong Lin, Saul J. Priceman, Mary C. Clark, Lior Goldberg, Stephen J. Forman, Xiuli Wang
Abstract
Dexamethasone (dex) is a glucocorticoid that is a mainstay for the treatment of inflammatory pathologies, including immunotherapy-associated toxicities, yet the specific impact of dex on the activity of CAR T cells is not fully understood. We assessed whether dex treatment given ex vivo or as an adjuvant in vivo with CAR T cells impacted the phenotype or function of CAR T cells. We demonstrated that CAR T cell expansion and function were not inhibited by dex. We confirmed this observation using multiple CAR constructs and tumor models, suggesting that this is a general phenomenon. Moreover, we determined that dex upregulated interleukin-7 receptor α on CAR T cells and increased the expression of genes involved in activation, migration, and persistence when supplemented ex vivo. Direct delivery of dex and IL-7 into tumor-bearing mice resulted in increased persistence of adoptively transferred CAR T cells and complete tumor regression. Overall, our studies provide insight into the use of dex to enhance CAR T cell therapy and represent potential novel strategies for augmenting CAR T cell function during production as well as following infusion into patients.